Search

VPM4001

VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. … It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

JB991

In addition a closely related cyclopentenone prostaglandin analogue has been shown to exert marked anti-inflammatory effect in vivo in an animal model. The drug will be applied topically on the skin. … The drug exerts marked antiproliferative and pro-apoptotic effect in human keratinocytes and fibroblasts in vitro.

R1626

It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effective in inhibiting viral replication … R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors.

4'-Methylene-5,8,10-trideazaaminopterin

CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier … It has been investigated for the treatment of Rheumatoid Arthritis (phase II).

Eritoran

Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

Cilansetron

Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.

Pheniprazine

In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.

Binodenoson

This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A_2A receptor.

PB127

Betaxolol

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.